Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting - Schedule of Segment Information (Details)

v3.20.2
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Net revenues - External $ 1,841,531 $ 5,190,650  
Net loss from continuing operations before income taxes (6,870,488) (12,932,795)  
Depreciation and amortization 164,707 223,586  
Capital expenditures 42,317  
Total assets 15,765,744   $ 14,707,659
Hospital Operations [Member]      
Net revenues - External 1,840,091 5,105,265  
Net loss from continuing operations before income taxes (3,092,933) (3,175,107)  
Depreciation and amortization 182,315 173,776  
Capital expenditures 42,317  
Total assets 13,186,606   14,275,256
Clinical Laboratory Operations [Member]      
Net revenues - External 1,440 85,385  
Net loss from continuing operations before income taxes (113,386) (225,530)  
Depreciation and amortization (17,743) 49,662  
Total assets 278,011   330,381
Corporate [Member]      
Net loss from continuing operations before income taxes (645,866) (1,072,835)  
Depreciation and amortization 135 148  
Total assets 4,531,979   2,305,380
Other Expense, Net [Member]      
Net loss from continuing operations before income taxes (3,018,303) $ (8,459,323)  
Assets of AMSG and HTS Classified as Held for Sale [Member]      
Total assets 487,278   514,772
Eliminations [Member]      
Total assets $ (2,718,130)   $ (2,718,130)